Chemomab Therapeutics Ltd DRC (NASDAQ:CMMB) — Market Cap & Net Worth
Market Cap & Net Worth: Chemomab Therapeutics Ltd DRC (CMMB)
Chemomab Therapeutics Ltd DRC (NASDAQ:CMMB) has a market capitalization of $17.95 Million ($17.95 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25542 globally and #5392 in its home market, demonstrating a -10.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chemomab Therapeutics Ltd DRC's stock price $2.45 by its total outstanding shares 7327660 (7.33 Million). Also see CMMB total assets for a full breakdown of the balance sheet.
Chemomab Therapeutics Ltd DRC Market Cap History: 2019 to 2026
Chemomab Therapeutics Ltd DRC's market capitalization history from 2019 to 2026. Data shows change from $164.14 Million to $17.95 Million (-42.91% CAGR). Also see CMMB cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Chemomab Therapeutics Ltd DRC is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #724 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2366 of 3165 |
Weight: Chemomab Therapeutics Ltd DRC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Chemomab Therapeutics Ltd DRC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chemomab Therapeutics Ltd DRC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Chemomab Therapeutics Ltd DRC (CMMB) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CMMB by Market Capitalization
Companies near Chemomab Therapeutics Ltd DRC in the global market cap rankings as of September 18, 2026. Review CMMB tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Chemomab Therapeutics Ltd DRC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Chemomab Therapeutics Ltd DRC Historical Marketcap From 2019 to 2026
Between 2019 and today, Chemomab Therapeutics Ltd DRC's market cap moved from $164.14 Million to $ 17.95 Million, with a yearly change of -42.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $17.95 Million | +48.48% |
| 2025 | $12.09 Million | -8.84% |
| 2024 | $13.26 Million | +254.90% |
| 2023 | $3.74 Million | -84.06% |
| 2022 | $23.45 Million | -53.62% |
| 2021 | $50.56 Million | -75.07% |
| 2020 | $202.83 Million | +23.57% |
| 2019 | $164.14 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Chemomab Therapeutics Ltd DRC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.95 Million USD |
| MoneyControl | $17.95 Million USD |
| MarketWatch | $17.95 Million USD |
| marketcap.company | $17.95 Million USD |
| Reuters | $17.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chemomab Therapeutics Ltd DRC
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical tri… Read more